PET Imaging Using 89ZrDFO-starPEG to Detect Tumor Activity in Adults with Solid Tumors

What this Trial Is About

Researchers are evaluating a new imaging agent called 89ZrDFO-starPEG in people with solid tumors. This first-in-human pilot study aims to gather early data on how this agent is taken up by tumors and the body, as well as its safety and radiation exposure. The goal is to support future use of this agent to help visualize how certain cancer treatments might accumulate in tumors. Participants receive a single intravenous microdose of 89ZrDFO-starPEG. They are divided into two groups one group undergoes multiple whole-body PET scans at several time points up to 9 days after injection, while the other group has a single PET scan between 5 and 9 days after injection. Urine and blood samples are also collected for additional studies. During the study, participants will be monitored for any side effects for about one week after the injection. Researchers will assess how much of the agent accumulates in tumors compared to normal tissue, measure radiation doses, and record any adverse events. The total participation time involves imaging and follow-up visits over approximately 9 days.

PET [89Zr]DFO-starPEG in Solid Tumors